Skip to content

Efficacy and safety of moxibustion for fatigue in peritoneal dialysis population: a randomized controlled pilot trial

Efficacy and safety of moxibustion for fatigue in peritoneal dialysis population: a randomized controlled pilot trial

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300070682
Enrollment
Unknown
Registered
2023-04-20
Start date
2023-02-17
Completion date
Unknown
Last updated
2023-06-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Peritoneal Dialysis-Related Fatigue

Interventions

Sponsors

Guangdong Provincial Hospital of Chinese Medicine,The Second Affiliated Hospital of Guangzhou University of Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: (1) Adults aged 18 years or older. (2) Maintenance peritoneal dialysis treatment for 4 months or longer before participating in the trial. (3) Fatigue symptom persisting for at least 4 weeks or longer, with a Piper Fatigue Inventory score of 4 or higher. (4) Able to communicate verbally, without communication or cognitive impairment. (5) Willing to participate in the trial and provide written consent.

Exclusion criteria

Exclusion criteria: (1) Life expectancy less than six months. (2) Patients on combined hemodialysis or had a kidney transplant history. (3) Combination of severe anemia, infection, acute exacerbation of heart failure, and other recent comorbidities that require adjustment of the peritoneal dialysis protocol. (4) Presence of impaired nutritional intake or moderate-to-severe malnutrition, or with serum albumin below 25 g/L. (5) Patients with skin lesions, rashes, petechiae and other conditions that make moxibustion inappropriate. (6) Patients had received therapies specific to fatigue symptom in four weeks before participating in the trial, including adjustment of dialysis protocol. (7) Patients have a history of hypersensitivity reactions or serious adverse events after moxibustion, or unable to follow moxibustion therapy for any reason. (8) Patients have any factor or disease other than end-stage renal disease that may contribute to fatigue (e.g., chronic wasting disease such as tumors). (9) Patients who are participating in other clinical trials.

Design outcomes

Secondary

MeasureTime frame
Peritoneal dialysis-related laboratory indicators(Blood creatinine, blood uremic nitrogen, serum albumin, hemoglobin, blood calcium, blood phosphorus, parathyroid hormone, urea clearance index (Kt/V), total creatinine clearance);Quality of Life Questionnaire (QLQ-C30);Pittsburgh quality index;Hospital Anxiety and Depression Scale;International Physical Activity Questionnaire – Short Form;

Primary

MeasureTime frame
Piper Fatigue Score;Proportion of subjects achieving target treatment regimen;

Countries

China

Contacts

Public ContactZhang La

Guangdong Provincial Hospital of Chinese Medicine, The Second Affiliated Hospital of Guangzhou University of ChineseMedicine

zhangla@gzucm.edu.cn+86 15920102784

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026